Previous Close | 21.17 |
Open | 21.17 |
Bid | 21.30 x 400 |
Ask | 21.49 x 100 |
Day's Range | 20.89 - 21.65 |
52 Week Range | 7.41 - 24.17 |
Volume | |
Avg. Volume | 1,478,855 |
Market Cap | 1.628B |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.08 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.25 |
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a monotherapy continues in parallel – SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two (2) new employees under
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript February 27, 2024 Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.56. Kura Oncology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]